Does the media refer more to NRSN or CRDF?

In the previous week, NeuroSense Therapeutics had 2 more articles in the media than Cardiff Oncology. MarketBeat recorded 4 mentions for NeuroSense Therapeutics and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.94 beat NeuroSense Therapeutics' score of 0.85 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroSense Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RANI or NRSN more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -206.46% -83.95% NeuroSense Therapeutics N/A N/A N/A

Does the media favor RANI or NRSN?

In the previous week, Rani Therapeutics and Rani Therapeutics both had 4 articles in the media. NeuroSense Therapeutics' average media sentiment score of 0.85 beat Rani Therapeutics' score of 0.61 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroSense Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NRSN or FRMM more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A Forum Markets N/A -242.09% -135.46%

Does the media prefer NRSN or FRMM?

In the previous week, Forum Markets had 3 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 7 mentions for Forum Markets and 4 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 0.85 beat Forum Markets' score of 0.70 indicating that NeuroSense Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroSense Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Forum Markets 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BTMD or NRSN?

In the previous week, NeuroSense Therapeutics had 1 more articles in the media than biote. MarketBeat recorded 4 mentions for NeuroSense Therapeutics and 3 mentions for biote. biote's average media sentiment score of 1.21 beat NeuroSense Therapeutics' score of 0.85 indicating that biote is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment biote 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroSense Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TELO or NRSN?

NeuroSense Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 1,066.78%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 NeuroSense Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has better valuation & earnings, TELO or NRSN?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A

Is TELO or NRSN more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -201.23% -172.71% NeuroSense Therapeutics N/A N/A N/A

Does the media favor TELO or NRSN?

In the previous week, NeuroSense Therapeutics had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 4 mentions for NeuroSense Therapeutics and 2 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.94 beat NeuroSense Therapeutics' score of 0.85 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telomir Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroSense Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NeuroSense Therapeutics (NRSN) Competitors

$0.73 +0.01 (+1.19%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$0.72 0.00 (-0.62%)

As of 07/10/2026 06:13 PM Eastern

Compare

NRSN vs. CRDF, RANI, FRMM, BTMD, and TELO

Should you buy NeuroSense Therapeutics stock or one of its competitors? MarketBeat compares NeuroSense Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeuroSense Therapeutics include Cardiff Oncology (CRDF), Rani Therapeutics (RANI), Forum Markets (FRMM), biote (BTMD), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry.

How does NeuroSense Therapeutics compare to Cardiff Oncology?

NeuroSense Therapeutics (NASDAQ:NRSN) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

NeuroSense Therapeutics presently has a consensus target price of $8.50, indicating a potential upside of 1,066.78%. Cardiff Oncology has a consensus target price of $7.50, indicating a potential upside of 463.91%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe NeuroSense Therapeutics is more favorable than Cardiff Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

NeuroSense Therapeutics has higher earnings, but lower revenue than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Cardiff Oncology	$590K	154.12	-$45.85M	-$0.67	N/A

In the previous week, NeuroSense Therapeutics had 2 more articles in the media than Cardiff Oncology. MarketBeat recorded 4 mentions for NeuroSense Therapeutics and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.94 beat NeuroSense Therapeutics' score of 0.85 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroSense Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by company insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

NeuroSense Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

NeuroSense Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. NeuroSense Therapeutics' return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%

Summary

NeuroSense Therapeutics beats Cardiff Oncology on 12 of the 15 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

NeuroSense Therapeutics has lower revenue, but higher earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	52.23	-$29.67M	-$0.41	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A

Rani Therapeutics presently has a consensus price target of $8.75, indicating a potential upside of 1,173.28%. NeuroSense Therapeutics has a consensus price target of $8.50, indicating a potential upside of 1,066.78%. Given Rani Therapeutics' higher probable upside, equities research analysts plainly believe Rani Therapeutics is more favorable than NeuroSense Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

NeuroSense Therapeutics' return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
NeuroSense Therapeutics	N/A	N/A	N/A

Rani Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Rani Therapeutics and Rani Therapeutics both had 4 articles in the media. NeuroSense Therapeutics' average media sentiment score of 0.85 beat Rani Therapeutics' score of 0.61 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroSense Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NeuroSense Therapeutics beats Rani Therapeutics on 8 of the 13 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Forum Markets?

NeuroSense Therapeutics (NASDAQ:NRSN) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

NeuroSense Therapeutics has higher earnings, but lower revenue than Forum Markets. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Forum Markets	$9.41M	8.49	-$450.52M	-$36.07	N/A

In the previous week, Forum Markets had 3 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 7 mentions for Forum Markets and 4 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 0.85 beat Forum Markets' score of 0.70 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroSense Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Forum Markets	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroSense Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market. Comparatively, Forum Markets has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

NeuroSense Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 1,066.78%. Forum Markets has a consensus price target of $10.00, suggesting a potential upside of 67.79%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe NeuroSense Therapeutics is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 4.1% of Forum Markets shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by insiders. Comparatively, 15.1% of Forum Markets shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

NeuroSense Therapeutics' return on equity of 0.00% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Forum Markets	N/A	-242.09%	-135.46%

Summary

NeuroSense Therapeutics beats Forum Markets on 10 of the 14 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to biote?

biote (NASDAQ:BTMD) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

biote has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

biote currently has a consensus price target of $2.75, indicating a potential upside of 18.03%. NeuroSense Therapeutics has a consensus price target of $8.50, indicating a potential upside of 1,066.78%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe NeuroSense Therapeutics is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

biote has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.46	$27.05M	$0.44	5.30
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A

21.7% of biote shares are owned by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 32.4% of biote shares are owned by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

biote has a net margin of 8.29% compared to NeuroSense Therapeutics' net margin of 0.00%. NeuroSense Therapeutics' return on equity of 0.00% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-25.72%	15.12%
NeuroSense Therapeutics	N/A	N/A	N/A

In the previous week, NeuroSense Therapeutics had 1 more articles in the media than biote. MarketBeat recorded 4 mentions for NeuroSense Therapeutics and 3 mentions for biote. biote's average media sentiment score of 1.21 beat NeuroSense Therapeutics' score of 0.85 indicating that biote is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
biote	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroSense Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

biote beats NeuroSense Therapeutics on 10 of the 15 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

NeuroSense Therapeutics' return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
NeuroSense Therapeutics	N/A	N/A	N/A

In the previous week, NeuroSense Therapeutics had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 4 mentions for NeuroSense Therapeutics and 2 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.94 beat NeuroSense Therapeutics' score of 0.85 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telomir Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroSense Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroSense Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 1,066.78%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Telomir Pharmaceuticals has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A

1.0% of NeuroSense Therapeutics shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

NeuroSense Therapeutics beats Telomir Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Get NeuroSense Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRSN vs. The Competition

Export

Metric	NeuroSense Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.72M	$3.71B	$7.09B	$12.66B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-1.35	21.64	27.42	24.53
Price / Sales	N/A	323.81	528.33	96.17
Price / Cash	N/A	143.33	48.47	60.03
Price / Book	-14.57	8.41	10.88	6.38
Net Income	-$11.12M	$23.85M	$3.59B	$331.87M
7 Day Performance	2.90%	-0.75%	-0.26%	0.37%
1 Month Performance	-0.91%	8.68%	4.55%	0.59%
1 Year Performance	-64.81%	55.85%	29.86%	22.26%

NeuroSense Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRSN NeuroSense Therapeutics	3.4888 of 5 stars	$0.73 +1.2%	$8.50 +1,066.8%	-64.8%	$23.72M	N/A	N/A	10
CRDF Cardiff Oncology	3.5957 of 5 stars	$1.34 +2.7%	$9.80 +634.1%	-67.3%	$91.27M	$590K	N/A	20	News Coverage Gap Down
RANI Rani Therapeutics	1.9068 of 5 stars	$0.71 -11.1%	$8.75 +1,141.1%	+6.7%	$87.46M	$1.63M	N/A	110	News Coverage
FRMM Forum Markets	3.3203 of 5 stars	$6.00 -11.9%	$10.00 +66.6%	N/A	$87.24M	$6.55M	N/A	7	News Coverage
BTMD biote	4.4535 of 5 stars	$2.30 +0.7%	$2.75 +19.8%	-42.9%	$86.25M	$188.16M	5.22	194	News Coverage Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRSN) was last updated on 7/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroSense Therapeutics (NRSN) Competitors

NRSN vs. CRDF, RANI, FRMM, BTMD, and TELO

How does NeuroSense Therapeutics compare to Cardiff Oncology?

Summary

How does NeuroSense Therapeutics compare to Rani Therapeutics?

Summary

How does NeuroSense Therapeutics compare to Forum Markets?

Summary

How does NeuroSense Therapeutics compare to biote?

Summary

How does NeuroSense Therapeutics compare to Telomir Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN vs. The Competition

NeuroSense Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeuroSense Therapeutics (NRSN) Competitors

NRSN vs. CRDF, RANI, FRMM, BTMD, and TELO

How does NeuroSense Therapeutics compare to Cardiff Oncology?

Do analysts prefer NRSN or CRDF?

Which has stronger valuation and earnings, NRSN or CRDF?

Does the media refer more to NRSN or CRDF?

Do insiders & institutionals have more ownership in NRSN or CRDF?

Which has more risk & volatility, NRSN or CRDF?

Is NRSN or CRDF more profitable?

Summary

How does NeuroSense Therapeutics compare to Rani Therapeutics?

Which has stronger valuation and earnings, RANI or NRSN?

Do analysts prefer RANI or NRSN?

Is RANI or NRSN more profitable?

Which has more volatility & risk, RANI or NRSN?

Do insiders and institutionals believe in RANI or NRSN?

Does the media favor RANI or NRSN?

Summary

How does NeuroSense Therapeutics compare to Forum Markets?

Which has preferable earnings & valuation, NRSN or FRMM?

Does the media prefer NRSN or FRMM?

Which has more volatility and risk, NRSN or FRMM?

Do analysts prefer NRSN or FRMM?

Do insiders & institutionals believe in NRSN or FRMM?

Is NRSN or FRMM more profitable?

Summary

How does NeuroSense Therapeutics compare to biote?

Which has more risk & volatility, BTMD or NRSN?

Do analysts recommend BTMD or NRSN?

Which has higher earnings & valuation, BTMD or NRSN?

Do insiders and institutionals believe in BTMD or NRSN?

Is BTMD or NRSN more profitable?

Does the media favor BTMD or NRSN?

Summary

How does NeuroSense Therapeutics compare to Telomir Pharmaceuticals?

Is TELO or NRSN more profitable?

Does the media favor TELO or NRSN?

Do analysts prefer TELO or NRSN?

Which has more volatility and risk, TELO or NRSN?

Which has better valuation & earnings, TELO or NRSN?

Do insiders and institutionals hold more shares of TELO or NRSN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN vs. The Competition

NeuroSense Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools